Other substances

Genz-123346

A glucosylceramide synthase inhibitor.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

Genz-123346 a glucosylceramide synthase inhibitor and Cerdelga® analogue. It was shown to inhibit SARS-CoV-2 replication in vitro (Vitner et al., 2021).

Genz-123346 on PubChem

Synonyms

Genz-346; Genz-123346 free base

 

Structure image - Genz-123346

CCCCCCCCC(=O)N[C@H](CN1CCCC1)[C@@H](C2=CC3=C(C=C2)OCCO3)O

Supporting references

Link Tested on Impact factor Notes Publication date
Glucosylceramide synthase inhibitors prevent replication of SARS-CoV-2 and Influenza virus
Small molecule In vitro 		Vero E6 cells; SARS-CoV-2 clinical isolate EPI_ISL_406862 [GISAID] 4.24

The compound inhibited SARS-CoV-2 infection with an IC50 of 2.7 μM and an SI of >17. It was active likely due to glucosylceramide synthase inhibition at the early stages of viral replication.

 Feb/24/2021
Export (.csv)